The SANFORD Guide to Antimicrobial Therapy 2026

The Sanford Guide to Antimicrobial Therapy 2026 (56th edition)

Sanford Guide helps you make the best infectious diseases treatment decisions, fast. Designed to be an invaluable resource for clinicians involved with ID in any care setting.

What's New for 2026

The 2025-2026 respiratory virus season remains dominated by the triple threat posed by COVID-19, RSV and influenza. Measles outbreaks are a continuing concern. Vaccination remains the cornerstone of prevention. For comprehensive coverage, we direct you to Sanford Guide digital content (sold separately - please inquire), which is constantly updated.

Throughout this edition we have updated treatment recommendations based on recent references and guidelines. Also, we have removed many older references that have been superseded or are simply no longer necessary.

Major updates include:

• Table 1—major updates to native valve endocarditis, adult arthritis, complicated urinary tract infections and plague, as well as minor updates to regimens and comments throughout
• Table 3—duration of therapy, is substantially revised
• Tables 5 and 6—highly resistant bacteria, are substantially revised
• Table 7—new desensitization protocols and references added
• Table 10A—gets recently approved anti-infectives
• Table 12A—pulmonary tuberculosis has a major update
• Tables 11, 13 and 14—covering fungal, parasitic and viral infections respectively are updated as needed
• Table 15—prophylaxis for dental procedures and candida and cocci prevention are updated for improved clarity
• New tables 18A, 18B—cover hepatic impairment dosing and DRESS
• Drug information tables covering pediatric dosing, pharmacology, enzyme- and transporter-mediated interactions, renal impairment dosing, obesity dosing are updated throughout.

Some recommendations may suggest the use of antimicrobial agents for indications or in doses that differ from the approved full prescribing information. Any such recommendations are based on published reports in peer-reviewed literature with citation to evidence-based references. They are not made based on input from any manufacturer and are made with due consideration for the concerns of the U.S. FDA regarding “off-label” uses.